Compare TYRA & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | PLUS |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2021 | 1996 |
| Metric | TYRA | PLUS |
|---|---|---|
| Price | $30.53 | $79.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $47.50 | N/A |
| AVG Volume (30 Days) | ★ 949.6K | 274.1K |
| Earning Date | 05-06-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 1.20% |
| EPS Growth | N/A | ★ 24.20 |
| EPS | N/A | ★ 5.03 |
| Revenue | N/A | ★ $2,442,549,000.00 |
| Revenue This Year | N/A | $19.83 |
| Revenue Next Year | N/A | $4.36 |
| P/E Ratio | ★ N/A | $15.75 |
| Revenue Growth | N/A | ★ 18.07 |
| 52 Week Low | $9.10 | $62.11 |
| 52 Week High | $40.65 | $93.98 |
| Indicator | TYRA | PLUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 41.24 |
| Support Level | $24.77 | $77.97 |
| Resistance Level | $31.57 | $90.93 |
| Average True Range (ATR) | 1.94 | 3.42 |
| MACD | 0.54 | -0.41 |
| Stochastic Oscillator | 87.95 | 15.08 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.